S&P 500   3,619.24 (-0.58%)
DOW   28,960.84 (-0.91%)
QQQ   270.76 (-0.41%)
AAPL   140.28 (-1.54%)
MSFT   235.48 (-0.85%)
META   137.41 (+0.73%)
GOOGL   96.77 (-0.67%)
AMZN   114.70 (-0.09%)
TSLA   267.40 (-0.30%)
NVDA   123.00 (+0.65%)
NIO   15.88 (+1.93%)
BABA   80.56 (+1.90%)
AMD   64.12 (-0.03%)
T   15.41 (-0.77%)
MU   50.88 (+1.74%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.45 (-0.45%)
DIS   95.80 (-1.69%)
AMC   7.14 (+0.56%)
PYPL   87.21 (-1.68%)
PFE   44.21 (+0.11%)
NFLX   239.70 (+0.00%)
S&P 500   3,619.24 (-0.58%)
DOW   28,960.84 (-0.91%)
QQQ   270.76 (-0.41%)
AAPL   140.28 (-1.54%)
MSFT   235.48 (-0.85%)
META   137.41 (+0.73%)
GOOGL   96.77 (-0.67%)
AMZN   114.70 (-0.09%)
TSLA   267.40 (-0.30%)
NVDA   123.00 (+0.65%)
NIO   15.88 (+1.93%)
BABA   80.56 (+1.90%)
AMD   64.12 (-0.03%)
T   15.41 (-0.77%)
MU   50.88 (+1.74%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.45 (-0.45%)
DIS   95.80 (-1.69%)
AMC   7.14 (+0.56%)
PYPL   87.21 (-1.68%)
PFE   44.21 (+0.11%)
NFLX   239.70 (+0.00%)
S&P 500   3,619.24 (-0.58%)
DOW   28,960.84 (-0.91%)
QQQ   270.76 (-0.41%)
AAPL   140.28 (-1.54%)
MSFT   235.48 (-0.85%)
META   137.41 (+0.73%)
GOOGL   96.77 (-0.67%)
AMZN   114.70 (-0.09%)
TSLA   267.40 (-0.30%)
NVDA   123.00 (+0.65%)
NIO   15.88 (+1.93%)
BABA   80.56 (+1.90%)
AMD   64.12 (-0.03%)
T   15.41 (-0.77%)
MU   50.88 (+1.74%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.45 (-0.45%)
DIS   95.80 (-1.69%)
AMC   7.14 (+0.56%)
PYPL   87.21 (-1.68%)
PFE   44.21 (+0.11%)
NFLX   239.70 (+0.00%)
S&P 500   3,619.24 (-0.58%)
DOW   28,960.84 (-0.91%)
QQQ   270.76 (-0.41%)
AAPL   140.28 (-1.54%)
MSFT   235.48 (-0.85%)
META   137.41 (+0.73%)
GOOGL   96.77 (-0.67%)
AMZN   114.70 (-0.09%)
TSLA   267.40 (-0.30%)
NVDA   123.00 (+0.65%)
NIO   15.88 (+1.93%)
BABA   80.56 (+1.90%)
AMD   64.12 (-0.03%)
T   15.41 (-0.77%)
MU   50.88 (+1.74%)
CGC   2.78 (+0.00%)
F   11.31 (-1.39%)
GE   62.45 (-0.45%)
DIS   95.80 (-1.69%)
AMC   7.14 (+0.56%)
PYPL   87.21 (-1.68%)
PFE   44.21 (+0.11%)
NFLX   239.70 (+0.00%)
NASDAQ:OBSV

ObsEva - OBSV Stock Forecast, Price & News

$0.14
+0.00 (+0.83%)
(As of 09/30/2022 02:24 PM ET)
Add
Compare
Today's Range
$0.14
$0.15
50-Day Range
$0.14
$1.62
52-Week Range
$0.13
$3.17
Volume
5,750 shs
Average Volume
1.59 million shs
Market Capitalization
$11.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40

ObsEva MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
5,895.7% Upside
$8.40 Price Target
Short Interest
Healthy
3.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of ObsEva in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.64) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

625th out of 1,097 stocks

Pharmaceutical Preparations Industry

300th out of 548 stocks

OBSV stock logo

About ObsEva (NASDAQ:OBSV) Stock

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com
ObsEva Receives Nasdaq Non-Compliance Notice
ObsEva: Q2 Earnings Insights - Benzinga
ObsEva Files Second Quarter 2022 Financial Statements
See More Headlines
Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Company Calendar

Last Earnings
8/17/2022
Today
9/30/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBSV
Fax
N/A
Employees
48
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+5,693.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-58,380,000.00
Pretax Margin
-1,310.79%

Debt

Sales & Book Value

Annual Sales
$20.11 million
Book Value
$0.41 per share

Miscellaneous

Free Float
N/A
Market Cap
$11.31 million
Optionable
Not Optionable
Beta
0.29

Key Executives

  • Mr. Brian O'Callaghan (Age 53)
    CEO & Director
    Comp: $1.12M
  • Dr. Ernest Loumaye M.D. (Age 70)
    OB/GYN, Ph.D., Co-Founder & Director
    Comp: $62k
  • Dr. Jean-Pierre Gotteland Ph.D. (Age 57)
    Chief Scientific Officer and Head of R&D
  • Mr. Fabien Lefebvre de Ladonchamps (Age 43)
    Chief Admin. Officer
  • Mr. Clive Bertram (Age 54)
    Chief Commercial Officer
  • Mr. Luigi Marro (Age 56)
    Chief Transformation Officer
  • Mr. William Michael Brown (Age 39)
    Chief Financial Officer
  • Ms. Delphine Renaud
    Personal Assistant to the CSO and Head of R&D
  • Ms. Katja Buhrer (Age 40)
    Chief Strategy Officer
  • Ms. Brandi Howard Ph.D.
    Chief Clinical Officer













OBSV Stock - Frequently Asked Questions

Should I buy or sell ObsEva stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OBSV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OBSV, but not buy additional shares or sell existing shares.
View OBSV analyst ratings
or view top-rated stocks.

What is ObsEva's stock price forecast for 2022?

5 brokerages have issued 1 year price targets for ObsEva's shares. Their OBSV share price forecasts range from $1.00 to $12.00. On average, they predict the company's stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 5,741.4% from the stock's current price.
View analysts price targets for OBSV
or view top-rated stocks among Wall Street analysts.

How have OBSV shares performed in 2022?

ObsEva's stock was trading at $1.99 at the beginning of 2022. Since then, OBSV stock has decreased by 92.8% and is now trading at $0.1438.
View the best growth stocks for 2022 here
.

When is ObsEva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our OBSV earnings forecast
.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) posted its quarterly earnings data on Wednesday, August, 17th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.06. The business had revenue of $2.61 million for the quarter, compared to analysts' expectations of $0.01 million.

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

How do I buy shares of ObsEva?

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $0.14.

How much money does ObsEva make?

ObsEva (NASDAQ:OBSV) has a market capitalization of $11.21 million and generates $20.11 million in revenue each year. The company earns $-58,380,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The official website for the company is www.obseva.com. The company can be reached via phone at (122) 552-3840 or via email at ir@obseva.ch.

This page (NASDAQ:OBSV) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.